Ningbo Univ. CDK1 compound 11l

Ningbo Univ. CDK1 compound 11l: sourced facts only. name: "Among them, 11l emerged as a highly promising lead compound, exhibiting nanomolar inhibitory activity against CDK1 (IC50 = 5.5 nM) with high selectivity over CDK2, Aurora A, and CDK4, showing selectivity indices of 4.7-, 14.1-, and 73.2-fold, respectively." [PMID:41903286]; target: "Among them, 11l emerged as a highly promising lead compound, exhibiting nanomolar inhibitory activity against CDK1 (IC50 = 5.5 nM) with high selectivity over CDK2, Aurora A, and CDK4, showing selectivity indices of 4.7-, 14.1-, and 73.2-fold, respectively." [PMID:41903286]; developer: "School of Pharmacy, Health Science Center, Ningbo University, Ningbo, 315211, China." [PMID:41903286]; stage: "In vivo efficacy evaluation demonstrated that 30 mg/kg 11l achieved a tumor growth inhibition (TGI) rate of 56.4%, without inducing significant body weight loss or observable organ toxicity." [PMID:41903286]